TreatmentEN_2012

8/3/2019 TreatmentEN_2012

1/78

Part 2: Recommendations for

Hypertension Treatment

2012 Canadian Hypertension

Education ProgramRecommendations


2/78

The full slide set of the2012 CHEP Recommendations

is available at

www.hypertension.ca


3/78

2012 Canadian Hypertension EducationProgram (CHEP)

A red flag has been posted whererecommendations were updated for 2012.

Slide kits for health care professional and publiceducation can be downloaded (English and Frenchversions) from www.hypertension.ca


4/78

Key CHEP Messages for theManagement of Hypertension

1. Assess blood pressure at all appropriate visits.

2. Maintaining a healthy lifestyle and weight lowers blood pressureand prevents hypertension. Promote: smoking cessation, healthydiet reducing dietary sodium and increased physical activity.

3. Lower blood pressure to


5/78

CHEP 2012 Recommendations

Whats new?

Out-of-office blood pressure measurements areimportant in both the diagnosis and management of

hypertension For patients with nondiabetic chronic kidney disease,

target blood pressure should be < 140/90 mmHg

For patients with systolic dysfunction and hypertension

ACE inhibitors, beta-blockers and (for most)aldosterone antagonists are recommended


6/78

For your patients ask themto sign up atwww.myBPsite.ca for freeaccess to the latest

information & resources onhigh blood pressure

For health care professionals sign up atwww.hypertension.ca forautomatic updates and

information on currenthypertension educationalresources


7/78

The Canadian Hypertension EducationProgram: 2012 Recommendations

Whats still important?

Lifestyle changes are a critical component ofhypertension management and prevention

The most important step in prescription ofantihypertensive therapy is achieving patient buy-in

Single pill combinations help achieve blood pressurecontrol

The management of hypertension is all about globalcardiovascular risk management and vascularprotection


8/78


Treatment Approaches:

Lifestyle

Pharmacological


9/78

Recommendations 2012Table of contents

I. Lifestyle ManagementII. Indications for drug therapyIII. Choice of therapyIV. Global vascular protectionV. Goal of therapy

VI. CV IHDVII. CHF

VIII. Cerebrovascular / StrokeIX. LVHX. Chronic kidney disease

XI. RenovascularXII. DiabetesXIII. Adherence strategies for patientsXIV.Endocrine


10/78

I. Lifestyle management




11/78

Lifestyle Recommendations forPrevention andTreatment of Hypertension

To reduce the possibility of becoming hypertensive,

Reduce sodium intake to less than 1500 mg/day

Healthy diet: high in fresh fruits, vegetables, low fat dairy products,dietary and soluble fibre, whole grains and protein from plant sources,low in saturated fat, cholesterol and salt in accordance with Canada'sGuide to Healthy Eating.

Regular physical activity: accumulation of 30-60 minutes of moderateintensity dynamic exercise 4-7 days per week in addition to dailyactivities

Low risk alcohol consumption: (2 standard drinks/day and lessthan 14/week for men and less than 9/week for women)

Attaining and maintaining ideal body weight (BMI 18.5-24.9 kg/m2)

Waist Circumference: Men


12/78

Dietary Sodium

Less than 2300mg / day

(Most of the salt in food is hidden and comesfrom processed food)

Dietary Potassium

Daily dietary intake >80 mmol

Calcium supplementation

No conclusive studies for hypertension

Magnesium supplementation

No conclusive studies for hypertension

Lifestyle Recommendations for Hypertension:Dietary

High in: Fresh fruits Fresh vegetables

Low fat dairy products Dietary and soluble fibre Plant protein

Low in:

Saturated fat and cholesterol Sodium

www.hc-sc.gc.ca/fn-an/food-guide-aliment/index-eng.php.


13/78

Potential Benefits of a Wide Spread Reductionin Dietary Sodium in Canada

1 million fewer hypertensives

5 million fewer physicians visits a year for hypertension Health care cost savings of $430 to 540 million per year related

to fewer office visits, drugs and laboratory costs for hypertension

Improvement of the hypertension treatment and control rate

13% reduction in CVD

Total health care cost savings of over $1.3 billion/year

1. Penz ED, Cdn J Cardiol 2008.2. Joffres MR_CJC_ 23(6) 2007.

Reduction in average dietary sodium from about3500 mg to 1700 mg1,2


14/78

Recommendations for adequate daily sodium intake

2,300 mg sodium (Na)

= 100 mmol sodium (Na)

= 5.8 g of salt (NaCl)

= 1 level teaspoon of

table salt

80% of average sodium intake is in processed foods

Only 10% is added at the table or in cooking

Age Adequate

Intake

(mg)

Upper

Limit

(mg)

19-50 1500 2300

51-70 1300 2300

71 and

over

1200 2300

Institute of Medicine, 2003


15/78

Sodium: Meta-analyses

The Cochrane Library2006;3:1-41

Average Reduction of sodiumin mg/day

1800 mg/day

2300 mg/day

Hypertensives

Reduction of BP

5.1 / 2.7 mmHg

7.2/3.8 mmHg

Average Reduction of sodiumin mg/day

1700 mg/day

2300 mg/day

Normotensives

Reduction of BP

2.0 / 1.0 mmHg

3.6/1.7 mmHg


16/78


Important messages from past recommendations

High dietary sodium is estimated to increase blood pressure inthe Canadian population to the extent that 1,000,000 Canadiansmeet the diagnostic criteria for hypertension who wouldotherwise have normal blood pressure

Most of the sodium in Canadian diets comes from processedfoods and restaurants.

Pizza, breads, soups and sauces usually have high amounts ofsodium

Patient information on how to achieve a reduced sodium diet

can be found at www.hypertension.ca

Aim to reduce dietary sodium intake to prevent and controlhypertension


17/78

Exercise should be prescribed as an adjunctive to pharmacological therapy

Lifestyle Recommendations for Hypertension:Physical Activity

Should be prescribed to reduce blood pressure

Frequency - Four to seven days per weekF

Intensity - ModerateI

Time - 30-60 minutesT

Type Cardiorespiratory Activity- Walking, jogging

- Cycling- Non-competitive swimming

T


18/78

Lifestyle Recommendations for Hypertension:Weight Loss

Height, weight, and waist circumference (WC) should be measured

and body mass index (BMI) calculated for all adults.

Hypertensive and all patients

BMIover 25- Encourage weight reduction

- Healthy BMI: 18.5-24.9 kg/m2

Waist CircumferenceMen


19/78

Courtesy J.P. Desprs 2006

Measure here

Iliac crest

Waist Circumference Measurement


20/78

Lifestyle Recommendations for Hypertension:Alcohol

Low risk alcohol consumption

Women: maximum of 9 standard drinks/week

Men: maximum of 14 standard drinks/week

0-2 standard drinks/day

A standard drink is about 142 ml or 5 oz of wine (12% alcohol). 341 mL or

12 oz of beer (5% alcohol) 43 mL or 1.5 oz of spirits (40% alcohol).


21/78

Lifestyle Recommendations for Hypertension:Stress Management

Hypertensive patientsin whom stress appears to be an important issue

Individualized cognitive behavioural interventions aremore likely to be effective when relaxation techniques

are employed.

Stress management

Behaviour Modification


22/78

Impact of Lifestyle Therapies on Blood Pressurein Hypertensive Adults

Intervention Intervention SBP/DBP

Reduce sodium intake-1800 mg/day sodium

Hypertensive

-5.1 / -2.7

Weight loss per kg lost -1.1 / -0.9

Alcohol intake -3.6 drinks/day -3.9 / -2.4

Aerobic exercise 120-150 min/week -4.9 / -3.7

Dietary patternsDASH diet

Hypertensive -11.4 / -5.5

Padwal R. et al. CMAJ SEPT. 27, 2005; 173 (7) 749-751


23/78

Lifestyle Therapies in Adults with Hypertension:Summary

Intervention Target

Reduce foods withadded sodium

< 2300 mg /day

Weight loss BMI


24/78

Epidemiologic impact on mortality of bloodpressure reduction in the population

Reduction in SBP(mmHg)

% Reduction in Mortality

Stroke CHD Total

2 -6 -4 -3

3 -8 -5 -4

5 -14 -9 -7

Adapted from Whelton, P. K. et al. JAMA 2002;288:1882-1888

AfterIntervention

BeforeIntervention

Reduction in BPPrevalence%


25/78

II. Indications for

Pharmacotherapy




26/78

II. Indications for Pharmacotherapy

Usual blood pressure threshold values for initiation

of pharmacological treatment of hypertension

Condition Initiation

SBP or DBP mmHg

Systolic or Diastolic hypertension u140/90

Diabetes

ChronicK

idney Disease

u130/80

u

140/90


27/78

II. Indications for Pharmacotherapyafter diagnosis of hypertension (1)

Patients at low risk with stage 1 hypertension(140-159/90-99 mmHg) lifestyle modification can be the sole therapy.

Patients with target organ damage (e.g. left

ventricular hypertrophy) (140-159/90-99 mmHg) Treat with pharmacotherapy

Patients with diabetes or chronic kidney diseaseshould be considered for pharmacotherapy if the

blood pressure is equal or over 140/90 mmHg


28/78

II. Indications for Pharmacotherapyafter diagnosis of hypertension (2)

Patients with other risk factors (over 90% ofCanadians with hypertension have other risk factors)(140-159/90-99 mmHg despite lifestyle modification)

Treat with pharmacotherapy

Treatment Gap Alert: Many younger hypertensiveCanadians with multiple cardiovascular risks arecurrently not treated with pharmacotherapy. Healthcare professionals need to be aware of this importantcare gap and recommend pharmacotherapy.


29/78

III. Choice of pharmacological

therapy




30/78

III. Choice of Pharmacological TreatmentUncomplicated

Associated risk factors?

or

Target organ damage/complications?

or

Concomitant diseases/conditions?

IndividualizedTreatment

(and compelling

indications)

YES

Treatment in theabsence of compelling

indications for specific

therapies

NO


31/78

III. Choice of Pharmacological Treatment

1. Treatment of Systolic/Diastolic hypertensionwithout other compelling indications

2. Treatment of Isolated Systolic hypertension without

other compelling indications


32/78

III. Treatment of Adults with Systolic/DiastolicHypertension without Other Compelling Indications

TARGET 20

mmHg systolic or >10 mmHg diastolic above target


33/78

III. Considerations Regarding the Choice ofFirst-Line Therapy

Use caution in initiating therapy with 2 drugs in whom adverseevents are more likely (e.g. frail elderly, those with posturalhypotension or who are dehydrated).

ACE inhibitors, renin inhibitors and ARBs are contraindicated inpregnancy and caution is required in prescribing to women of childbearing potential.

Beta blockers are not recommended as first line therapy for patientsage 60 and over without another compelling indication.

Diuretic-induced hypokalemia should be avoided through the use ofpotassium sparing agents if required.

The use of dual therapy with an ACE inhibitor and an ARB should

only be considered in selected and closely monitored people withadvanced heart failure or proteinuric nephropathy.

ACE-inhibitors are not recommended (as monotherapy)for black patients without another compelling indication.


34/78

III. Add-on Therapy for Systolic/DiastolicHypertension without Other Compelling Indications

IF BLOOD PRESSUREIS NOT

CONTROLLED CONSIDER

Nonadherence Secondary HTN Interfering drugs or lifestyle White coat effect

If blood pressure is still not controlled, or there are adverse effects,

other classes of antihypertensive drugs may be combined (such as

alpha blockers or centrally acting agents).

2.Triple or Quadruple Therapy

1. Add-on Therapy

If partial response to monotherapy


35/78

Drug Combinations

When combining drugs, use first-line therapies.

Two drug combinations of beta blockers, ACEinhibitors and angiotensin receptor blockers have notbeen proven to have additive hypotensive effects.

Therefore these potential two drug combinationsshould not be used unless there is a compelling (nonblood pressure lowering) indication

Combinations of an ACEI with an ARB do not reducecardiovascular events more than the ACEI alone andhave more adverse effects therefore are notgenerally recommended


36/78

Drug Combinations contd

Caution should be exercised in combining a nondihydropyridine CCB and a beta blocker to reducethe risk of bradycardia or heart block.

Monitor serum creatinine and potassium whencombining K sparing diuretics (such as aldosteroneantagonists), ACE inhibitors and/or angiotensinreceptor blockers.

If a diuretic is not used as first or second line therapy,

triple dose therapy should include a diuretic, whennot contraindicated.


37/78

Medication Use and BP Controlin ALLHAT

0

20

40

60

80

100

Baseline 6 mo 1 y 3 y 5 y

%

3 Drugs

2 Drugs

1 drug

% controlled-

Canadian sites

Cushman et al. J Clin Hypertens2002;4:393-404


38/78

Ratio of Incremental SBP lowering effect atstandard dose Combine or Double?

1.04 1

1.16

0.891.01

0.19 0.23 0.2

0.37

0.22

0

0.2

0.4

0.6

0.8

1

1.2

1.4

Thiazide -blocker ACE-I CCB All

Combine Double

Inc

remenalSBPr

eductionratio

Ob

served/Expected

(additive)

Wald et al, Combination Versus Monotherapy for Blood Pressure Reduction,The American Journal of Medicine, Vol 122, No 3, March 2009


39/78

BP lowering effects from antihypertensive drugs

Dose response curves for efficacy are relatively flat

80% of the BP lowering efficacy is achieved at half-standard dose

Combinations of standard doses have additive bloodpressure lowering effects

Law. BMJ 2003


40/78

III. Summary: Treatment of Systolic-DiastolicHypertension without Other Compelling Indications

CONSIDER

Nonadherence Secondary HTN Interfering drugs or

lifestyle White coat effect

Dual Combination

Triple or Quadruple

Therapy

Lifestyle modification

Thiazidediuretic

ACEILong-acting

CCBBeta-

blocker*

TARGET 20 mmHg systolicor>10 mmHg diastolic above target


41/78

III. Treatment Algorithm for Isolated SystolicHypertension without Other Compelling Indications

INITIAL TREATMENT AND MONOTHERAPY

Thiazide

diuretic

Long-acting

DHPCCB


therapy

ARB

TARGET


42/78

III. Add-on therapy for Isolated SystolicHypertension without Other Compelling Indications

CONSIDER

Nonadherence Secondary HTN Interfering drugs or


If blood pressure is still not controlled, or there are adverse

effects, other classes of antihypertensive drugs may be

combined (such as ACE inhibitors, alpha adrenergic

blockers, centrally acting agents, or nondihydropyridine

calcium channel blocker).

If partial response to monotherapy

Long-acting

DHPCCB

Triple therapy

Thiazide

diureticARB

Dual combinationCombine first line agents


43/78

III. Summary: Treatment of Isolated SystolicHypertension without Other Compelling Indications

CONSIDER

Nonadherence

Secondary HTN Interfering drugs or


Thiazidediuretic

Long-actingDHPCCB

Dual therapy

Triple therapy


therapy

ARB

TARGET


44/78

Choice of Pharmacological Treatmentfor Hypertension

Individualized treatment

Compelling indications: Ischemic Heart Disease

Recent ST Segment Elevation-MI or non-ST Segment Elevation-MI

Left Ventricular Systolic Dysfunction

Cerebrovascular Disease

Left Ventricular Hypertrophy Non Diabetic Chronic Kidney Disease

Renovascular Disease

Smoking

Diabetes Mellitus With Nephropathy

Without Nephropathy

Global Vascular Protection for Hypertensive Patients Statins if 3 or more additional cardiovascular risks

Aspirin once blood pressure is controlled


45/78

IV. Global Vascular Protection

for Patients with Hypertension




46/78

IV. Vascular Protection for HypertensivePatients: Statins

In addition to currentCanadian recommendations on management

of dyslipidemia, statins are recommended in high-risk

hypertensive patients with established atherosclerotic disease

or with at least 3 of the following criteria:

Male

Age 55 or older

Smoking

Total-C/HDL-C ratio of 6

mmol/L or higher

Family History of PrematureCV disease

LVH

ECG abnormalities

Microalbuminuria or Proteinuria

ASCOT-LLA Lancet 2003;361:1149-58


47/78

IV. Vascular Protection for HypertensivePatients: ASA

Consider low dose ASA

Caution should be exercised if BP is not controlled.


48/78

V. Goals of Therapy




49/78

49

Blood pressure target values for treatment of hypertensionCondition Target

SBP and DBP mmHg

Isolated systolic hypertension


50/78

V. Goals of Therapy

To optimally reduce cardiovascular risk reduce theblood pressure to specified targets.

This usually requires two or more drugs and lifestylechanges

The systolic target is more difficult to achieve howevercontrolling systolic blood pressure is as important if not moreimportant than controlling diastolic blood pressure


51/78

Follow-up of blood pressureabove targets

Patients with blood pressure above target arerecommended to be followed at least every 2ndmonth

Follow-up visits are used to increase the intensity oflifestyle and drug therapy, monitor the response totherapy and assess adherence


52/78

VI. Treatment of Hypertension in Patients withIschemic Heart Disease

Caution should be exercised when combining a non DHP-CCB and a beta-blocker If abnormal systolic left ventricular function: avoid non DHP-CCB (Verapamil or

Diltiazem) Dual therapy with an ACEI and an ARB are not recommended in the absence of

refractory heart failure The combination of an ACEi and CCB is preferred

1. Beta-blocker2. Long-acting CCB

Stable angina

ACEI are recommended for most

patients with established CAD*ARBs are not inferior to ACEI in IHD

Short-actingnifedipine

*Those at low risk with well controlled risk factors may not benefit from ACEI therapy


53/78

VI. Treatment of Hypertension in Patients with Recent STSegment Elevation-MI or non-ST Segment Elevation-MI

Long-acting

DihydropyridineCCB*

Beta-blocker

and ACEI or

ARB

Recent

myocardialinfarction

HeartFailure

?

NO

YES

Long-actingCCB

If beta-blockercontraindicated

or not effective

*Avoid non dihydropyridine CCBs (diltiazem, verapamil)


54/78

VII. Treatment of Hypertension with LeftVentricular Systolic Dysfunction

Beta-blockers used in clinical trials were bisoprolol, carvedilol and metoprolol.

If additional therapy is needed: Diuretic (Thiazide for hypertension; Loop for volume control)

forCHF classII-IV

or post MIand selected patients with L

V

dysfunction (see notes): Aldosterone Antagonist

Systoliccardiac

dysfunction

ACEI and Beta blocker if ACEI intolerant: ARBTitrate doses of ACEI or ARB to those used in clinical trials

If ACEI and ARB are contraindicated: Hydralazine and Isosorbidedinitrate in combination

If additional antihypertensive therapy is needed:

ACEI / ARB Combination Long-acting DHP-CCB (Amlodipine)NondihydropyridineCCB


55/78

VIII. Treatment of Hypertension in Association With StrokeAcute Stroke: Onset to 72 Hours

Treat extreme BP elevation (systolic

> 220 mmHg, diastolic > 120 mmHg)

by 15-25% over the first 24 hour

with gradual reduction after.

If eligible for thrombolytic therapytreat very high BP (>185/110 mmHg)

Acute

ischemic

Stroke

Avoid excessive lowering of BP which can exacerbate ischemia


56/78

VIII. Treatment of Hypertension in Association With StrokeAfter the acute Phase of Stroke or TIA

Strongly consider blood pressure reduction in all patients

after the acute phase of stroke orTIA .

Target BP < 140/90 mmHg

An ACEI / diuretic

combination is preferred

StrokeTIA

Combinations of an ACEI with an ARB are not recommended


57/78

IX. Treatment of Hypertension in Patients withLeft Ventricular Hypertrophy

Hypertensive patients with left ventricular hypertrophy should

be treated with antihypertensive therapy to lower the rate of

subsequent cardiovascular events

Vasodilators:

Hydralazine, Minoxidil can increase LVH

Left ventricular

hypertrophy

- ACEI- ARB,- CCB- Thiazide Diuretic- BB (if age below 60)*


58/78

X. Treatment of Hypertension in Patients withNon Diabetic Chronic Kidney Disease

Chronic kidney

disease and

proteinuria *

ACEI/ARB:Bilateral renalartery stenosis

ACEI or ARB (if ACEI tolerated)

Combination with other agents

Additive therapy: Thiazide diuretic.

Alternate: If volume overload: loop diuretic

Target BP: < 140/90 mmHg

* albumin:creatinine ratio [ACR] > 30 mg/mmol

orurinary protein > 500 mg/24hr

Monitor serum potassium and creatinine carefully in patients with CKD prescribed an ACEI or ARB

Combinations of a ACEI and a ARB are specifically not recommended in the absence of proteinuria


59/78

XI. Treatment of Hypertension in Patients withRenovascular Disease

Close follow-up and intervention (angioplasty and stenting or surgery) shouldbe considered for patients with: uncontrolled hypertension despite therapy

with three or more drugs, or deteriorating renal function, or bilateralatherosclerotic renal artery lesions (or tight atherosclerotic stenosis in a

single kidney), or recurrent episodes of flash pulmonary edema.

Does not imply specific

treatment choice

Renovascular

disease

Caution in the use of ACEI or ARB inbilateral renal artery stenosis orunilateral disease with solitary kidney


60/78

XII. Treatment ofHypertension in association

with Diabetes Mellitus2012 Canadian Hypertension


XII T f H i i i i


61/78

XII. Treatment of Hypertension in associationwith Diabetes Mellitus

Threshold equal or over 130/80 mmHg and Target below 130/80 mmHg

with

Nephropathy*

*Urinary albumin to creatinine

ratio > 2.0 mg/mmol in men or

> 2.8mg/mmol in women*

Diabetes

without

Nephropathy**

Isolated

Systolic

Hypertension

Systolic-

diastolic

Hypertension

* based on at least 2 of 3 measurements

A combination of 2 first line drugs maybe considered as initial therapy if theblood pressure is >20 mmHg systolicor>10 mmHg diastolic above target

Combinations of an ACEI with an ARB are specifically

not recommended in the absence of proteinuria

XII T t t f H t i i i ti


62/78

XII. Treatment of Hypertension in associationwith Diabetic Nephropathy

IfCreatinine over 150 mol/L or creatinine clearance below 30 ml/min ( 0.5

ml/sec), a loop diuretic should be substituted for a thiazide diuretic if control

of volume is desired

THRESHOLD equal or over 130/80 mmHg and TARGET below 130/80 mmHg

DIABETES

with

Nephropathy

ACEInhibitor

or ARB

IF ACEI and ARB arecontraindicated or not

tolerated,SUBSTITUTE

Long-actingCCB or

Thiazide diuretic

Addition of one or more ofLong-acting CCB or Thiazidediuretic

3 - 4 drugs combination maybe needed


2012 C di H t i Ed ti


63/78


Important messages from past recommendations

Patients with diabetes are at high cardiovascular risk

Most patients with diabetes have hypertension

Treatment of hypertension in patients with diabetes reducestotal mortality, myocardial infarction, stroke, retinopathy andprogressive renal failure rates.

Treating hypertension in patients with diabetes reduces deathand disability and reduces health care system costs

In diabetes, TARGET


64/78

XII. Treatment of Systolic-DiastolicHypertension without Diabetic Nephropathy

1. ACEInhibitor or ARB or

2. Dihydropyridine CCB or

Thiazide diuretic

IFACEInhibitor and ARB andDHP-CCB and Thiazide arecontraindicated or nottolerated,

SUBSTITUTE

Cardioselective BB* or

Long-actingNON DHP-CCB

More than 3 drugs may be needed to reach target values for diabetic patients

* Cardioselective BB: Acebutolol, Atenolol, Bisoprolol , Metoprolol

Threshold equal or over 130/80 mmHg and TARGET below 130/80 mmHg

Combination of first line

agents

Addition of one or more of:Cardioselective BB orLong-acting CCB

Diabetes

without

Nephropathy

DHP: dihydropyridine

Combinations of an ACEInhibitor with an ARB are specifically not recommended in theabsence of proteinuria

ACCORD St d R lt d ti l f l k


65/78

ACCORD Study: Results and rationale for lackof impact on BP recommendations

Overall BP study was neutral with no benefit of systolic target< 120 mmHg vs < 140 mmHg for primary outcome, yet:

Power issue: Annual rate of primary outcome 1.87% in theintensive arm versus 2.09% in the standard arm vs 4%/yearevent rate projected during sample size calculations

Significant interaction between BP and glycaemia controlstudies such that those in usual care glycaemia group (A1c7%+) had a significant improvement in primary outcome withlower BP target

Secondary outcome for stroke reduction showed a benefit forlower BP target (41% RRR)

Therefore no clear evidence supporting a change in BP targetsfor people with diabetes at this point

ACCORD study NEJM 2010

XII T t t f H t i i i ti


66/78

XII. Treatment of Hypertension in associationwith Diabetes Mellitus: Summary

More than 3 drugs may be needed to reach target values for diabetic patients

If Creatinine over 150 mol/L or creatinine clearance below 30 ml/min ( 0.5 ml/sec), a loop diuretic should be substituted for athiazide diuretic if control of volume is desired

Threshold equal or over 130/80 mmHg and TARGET below 130/80 mmHg

Diabetes

with

Nephropathy

> 2-drugcombinations

ACEInhibitor

or ARB

without

Nephropathy

1. ACEInhibitoror ARB

or

2. DHP-CCB orThiazidediuretic


Combinations of an ACEI with an ARB are specifically not recommended in the absence of proteinuria

A combination of 2 first linedrugs may be considered asinitial therapy if the bloodpressure is >20 mmHg systolicor >10 mmHg diastolic abovetarget. Combining an ACEi and

a DHP-CCB is recommended.


67/78

XIII. Adherence

2012 Canadian HypertensionEducation Program

Recommendations

XIII Adh t ti h t i t


68/78

XIII. Adherence to anti-hypertensive managementcan be improved by a multi-pronged approach

Assess adherence to pharmacological and non-pharmacological therapy at every visit

Teach patients to take their pills on a regular scheduleassociated with a routine daily activity e.g. brushingteeth.

Simplify medication regimens using long-acting once-daily dosing

Utilize fixed-dose combination pills

Utilize unit-of-use packaging e.g. blister packaging Replacing multiple pill antihypertensive combinations

with single pill combinations!

XIII Adherence to anti hypertensive management


69/78

XIII. Adherence to anti-hypertensive managementcan be improved by a multi-pronged approach

Encourage greater patient responsibility/autonomy inregular monitoring of their blood pressure

Educate patients and patients' families about theirdisease/treatment regimens verbally and in writing

Use an interdisciplinary care approach coordinatingwith work-site health care givers and pharmacists ifavailable

New Patient Resources for


70/78

New Patient Resources forHypertension Online

www.hypertension.ca/tools - Download current resources for the prevention andcontrol of hypertension

www.myBPsite.ca - Have your patients sign up to access the latest hypertensionresources

www.lowersodium.ca - Tools and resources for healthcare professionals to use ineducating other healthcare professionals, the public or patients about the risks of high

dietary sodium in Canada. www.sodium101.ca -To access a simple to use demonstration of food sodium content

for your patients

www.c-changeprogram.ca -To learn more about the harmonized recommendationsfor CVD prevention and treatment

www.heartandstroke.ca/BP -To monitor home blood pressure and encourage selfmanagement of lifestyle

www.canadianstrokenetwork.ca Download current resources to support bestpractice recommendations for stroke care

http://www.hypertension.qc.ca/ - Socit Qubcoise dhypertension artrielle


71/78

Public translation of CHEP recommendations

Hypertension recommendations for the public

Translated into 4 Indo-Asian languages (2007)

Based on CHEP guidelines (annually updated)

Download at www.hypertension.ca


72/78

Sodium Slide Kit

Tool used to educate the public and patients ondietary sodium.

Annually updated.



73/78

Brief Hypertension Action Tool

Can by used by a healthcare provider to better inform and engage a

hypertensive patient to ultimately become more active in their

care.

Involves 3 Action Tools:

Action Tool # 1 Explains High BP

Action Tool # 2 Self-management of

lifestyle

Action Tool # 3 Proper home measurement& information about medication


Measuring Blood Pressure the Right Way


74/78

Measuring Blood Pressure the Right Way Poster

Pocket cards can beordered from ourwebsite.

Brief highlights:1. Preparing to taking your

blood pressure

2. Using endorsed BPdevices.



75/78

Summary I

Regarding the treatment of hypertension, therecommendations endorse:

Know the current blood pressure of all your patients

Most Canadians will develop hypertension during their lives.

Routine assessment of blood pressure is required for earlydetection and risk management

Encourage the use of approved devices and propertechnique to measure blood pressure at home.

Most can assess blood pressure at home. Home measurement

can confirm a diagnosis of hypertension, improve adherence totherapy and control rates and detect patients with white coat ormasked hypertension.


76/78

Summary II


Assess and manage CV risk in hypertensives

high dietary sodium intake, smoking, dyslipidemia,dysglycemia, abdominal obesity, unhealthy eating, and physical

inactivity.

LIFESTYLE MODIFICATION

Sustained lifestyle modification is the cornerstone for theprevention and control of hypertension and the management ofcardiovascular disease. Encourage patients to reduce theirsodium intake according to Health Canadas recommendations.


77/78

Summary III


TREATING TO TARGET BP Treat blood pressure to less than


78/78

For your patients ask themto sign up atwww.myBPsite.ca for freeaccess to the latestinformation & resources on

high blood pressure

For health care professionals sign up atwww.hypertension.ca forautomatic updates and oncurrent hypertension

educational resources

Documents

TreatmentEN_2012